The Latest Cardiac and Vascular News
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-March – – […]
LONDON, May 16, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million. Cost reduction programs implemented across the global organization resulting in declining operating […]
Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision Company Completed a Phase 1C Study in Healthy Volunteers in Australia Affirming Proposed Revised DM199 IV Dose of 0.5 µg/kg for Continuing the […]
SINGAPORE, MAY 15, 2023 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President of Genesis MedTech Intervention, North America and CEO of JC Medical, Inc. Dr. Turco will lead the commercial strategy for the Vascular Interventions and Structural Heart Franchises […]
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention […]
heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of […]
GUILFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable, point-of-care MRI system, today announced first quarter 2023 financial results and provided a business update. “We had strong growth at Hyperfine in the […]
CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the […]
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May […]
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit — — First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, May […]
